Published in:
01-06-2018 | Review Article
Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice
Authors:
Vishal Jindal, Ena Arora, Muhammad Masab, Sorab Gupta
Published in:
Medical Oncology
|
Issue 6/2018
Login to get access
Abstract
Chimeric antigen receptor (CAR) T cell therapy is genetically engineered tumor antigen-specific anticancer immunotherapy, which after showing great success in hematological malignancies is currently being tried in advanced solid tumors like pancreatic cancer. Immunosuppressive tumor microenvironment and dense fibrous stroma are some of the limitation in the success of this novel therapy. However, genetic modifications and combination therapy is the topic of the research to improve its efficacy. In this article, we summarize the current state of knowledge, limitations, and future prospects for CAR T cell therapy in pancreatic cancer.